Physician profile
Nathan Reed
NPI 1467148536
$4,514.25
in general payments reported to CMS, 2019-2025
28 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,087 · 2024: $1,688 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,455 · Education: $59.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,455.19 |
| Education | $59.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.44 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $645.62 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $550.84 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Axsome Therapeutics, INC. | $312.40 | 2023-2025 | Auvelity |
| Lundbeck LLC | $289.80 | 2023-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $276.80 | 2023-2025 | Hyqvia, Trintellix |
| Idorsia Pharmaceuticals US INC | $167.81 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $159.43 | 2023-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Argenx US, INC. | $145.33 | 2025 | Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $121.28 | 2023-2025 | Ingrezza |
| Eisai INC. | $120.27 | 2024-2025 | |
| Alkermes, INC. | $114.83 | 2023-2025 | Lybalvi |
| Almatica Pharma LLC | $111.79 | 2024-2025 | Loreev Xr |
| Biogen, INC. | $109.21 | 2024-2025 | Vumerity, Tysabri |
| Vanda Pharmaceuticals INC. | $97.07 | 2024-2025 | Hetlioz, Fanapt |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $94.45 | 2023-2024 | Aplenzin |
| Tris Pharma INC | $92.76 | 2023-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $90.61 | 2024-2025 | Xelstrym, Secuado |
| Teva Pharmaceuticals USA, INC. | $81.42 | 2024-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $65.19 | 2024-2025 | Cobenfy |
| Tg Therapeutics, INC. | $54.19 | 2025 | |
| Lilly USA, LLC | $23.44 | 2025 | Kisunla |
| Emd Serono, INC. | $22.69 | 2024 | Mavenclad |
| Acadia Pharmaceuticals INC | $21.07 | 2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $19.57 | 2024 | Ultomiris |
| Livanova USA, INC. | $19.16 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Amneal Pharmaceuticals LLC | $15.20 | 2025 | Crexont |
| Cycle Pharmaceuticals INC | $14.58 | 2025 | Bafiertam, Tascenso Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.